Similar articles

• [A recombinant vaccinia virus expressing the middle preS2-S envelope protein of the hepatitis B virus. The induction of humoral and cellular immunity by the immunization of laboratory animals].

  Beliaev AS, Dmitriev IP, Ignat'ev GM, Mizenko GA, Putintseva NI, Sabirov AN, Samukov VV, Semënova LN, Ammosov AD, Rukavishnikov MIu, et al. Beliaev AS, et al. Dokl Akad Nauk SSSR. 1990;314(2):488-91. Dokl Akad Nauk SSSR. 1990. PMID: 2265587 Russian. No abstract available.
• Vaccinia virus vectors.

  Moss B. Moss B. Biotechnology. 1992;20:345-62. doi: 10.1016/b978-0-7506-9265-6.50021-x. Biotechnology. 1992. PMID: 1600384 Review. No abstract available.
• Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.

  Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HG, Lunn DP. Breathnach CC, et al. Vaccine. 2006 Feb 20;24(8):1180-90. doi: 10.1016/j.vaccine.2005.08.091. Epub 2005 Sep 12. Vaccine. 2006. PMID: 16194586
• Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.

  Harrer E, Bäuerle M, Ferstl B, Chaplin P, Petzold B, Mateo L, Handley A, Tzatzaris M, Vollmar J, Bergmann S, Rittmaier M, Eismann K, Müller S, Kalden JR, Spriewald B, Willbold D, Harrer T. Harrer E, et al. Antivir Ther. 2005;10(2):285-300. Antivir Ther. 2005. PMID: 15865223 Clinical Trial.
• Vaccinia virus recombinants as potential herpes simplex virus vaccines.

  Rooney JF, Wohlenberg CR, Notkins AL. Rooney JF, et al. Adv Exp Med Biol. 1992;327:183-9. doi: 10.1007/978-1-4615-3410-5_20. Adv Exp Med Biol. 1992. PMID: 1338264 Review. No abstract available.